Table 1.
Clinical and demographic characteristics: comparison of underweight and normal-weight patients (BMI > 25) with overweight and obese patients (BMI ≥ 25) (n = 272).
| Clinical Characteristics | Underweight or Normal Weight (BMI < 25) (n = 179) |
Overweight or Obese (BMI ≥ 25) (n = 93) |
Overall Population (n = 272) |
p-Value |
|---|---|---|---|---|
| Age, mean (SD) | 59.4 (12.2) | 65.3 (9.89) | 61.4 (11.8) | <0.001 |
| Sex, n (%) | 0.02 | |||
| Men | 105 (58.7) | 69 (74.2) | 174 (64) | |
| Women | 74 (41.3) | 24 (25.8) | 98 (36) | |
| Primary tumor, n (%) | 0.16 | |||
| Non-small cell lung cancer | 93 (52.0) | 43 (46.2) | 136 (50.0) | |
| Head and neck squamous cell carcinoma | 29 (16.2) | 7 (7.5) | 36 (13.2) | |
| Digestive tumor | 16 (8.9) | 8 (8.6) | 24 (8.8) | |
| Renal cell carcinoma | 14 (7.8) | 10 (10.8) | 24 (8.8) | |
| Melanoma | 12 (6.7) | 10 (10.8) | 22 (8.1) | |
| Urothelial carcinoma | 9 (5.0) | 10 (10.8) | 19 (7.0) | |
| Other | 6 (3.4) | 5 (5.3) | 11 (4.0) | |
| MSI status, n (%) | 0.56 | |||
| MSI-H | 14 (7.8) | 10 (10.8) | 24 (8.8) | |
| No information or negative | 165 (92.2) | 83 (89.2) | 248 (91.2) | |
| PDL1 (N = 138), n (%) | 0.48 | |||
| >1% | 73 (40.8) | 31 (33.3) | 104 (38.2) | |
| ≤1% | 22 (12.2) | 12 (13) | 34 (12.5) | |
| Treatment, n (%) | 0.25 | |||
| Nivolumab | 80 (44.7) | 34 (36.6) | 114 (41.9) | |
| Pembrolizumab | 64 (35.8) | 39 (41.9) | 103 (37.9) | |
| Nivolumab + ipilimumab | 10 (5.6) | 9 (9.7) | 19 (7) | |
| Durvalumab + Tremelimumab | 9 (5) | 5 (5.4) | 14 (5.1) | |
| Atezolizumab | 11 (6.1) | 2 (2.2) | 13 (4.8) | |
| Durvalumab | 5 (2.8) | 2 (2.2) | 7 (2.6) | |
| Ipilimumab | 0 | 1 (1) | 1 (0.4) | |
| Avelumab | 0 | 1 (1) | 1 (0.4) | |
| Performance status, n (%) | <0.01 | |||
| 0 | 29 (16.2) | 29 (31.2) | 58 (21.3) | |
| 1 | 99 (55.3) | 58 (62.4) | 157 (57.7) | |
| 2 | 42 (23.5) | 6 (6.4) | 48 (17.6) | |
| 3 | 8 (4.5) | 0 | 8 (2.9) | |
| 4 | 1 (1) | 0 | 1 (1) | |
| Place of immunotherapy in the course of treatment, n (%) | 0.59 | |||
| First line | 50 (27.9) | 31 (33.3) | 81 (29.8) | |
| Second line | 99 (55.3) | 53 (57.0) | 152 (55.9) | |
| Third line | 19 (10.6) | 7 (7.5) | 26 (9.6) | |
| >Third line | 11 (6.1) | 2 (2.2) | 13 (4.7) | |
| Number of toxicities in patients, n (%) | 0.17 | |||
| No toxicity | 56 (61.5) | 50 (53.8) | 160 (58.8) | |
| One toxicity | 54 (30.1) | 31 (33.3) | 85 (31.2) | |
| Two toxicities | 15 (8.4) | 10 (10.7) | 25 (9.2) | |
| Three toxicities | 0 | 2 (2.2) | 2 (1) | |
| Type of toxicity, n (%) | 0.47 | |||
| Thyroiditis | 22 (12.3) | 12 (12.9) | 34 (12.5) | |
| Rheumatologic toxicity | 14 (7.8) | 10 (10.7) | 24 (8.8) | |
| Diarrhea and/or colitis | 14 (7.8) | 6 (6.4) | 20 (7.4) | |
| Cutaneous toxicity | 12 (6.7) | 6 (6.4) | 18 (6.6) | |
| Hepatitis | 7 (4) | 6 (6.4) | 13 (4.8) | |
| Pneumonitis | 6 (3.4) | 7 (7.5) | 13 (4.8) | |
| Other | 9 (5) | 10 (10.7) | 19 (7) | |
| Toxicity grade, n (%) | 0.46 | |||
| Grade I | 31 (17.3) | 21 (22.6) | 52 (19.1) | |
| Grade II | 32 (17.9) | 23 (24.7) | 55 (20.2) | |
| Grade III | 15 (8.3) | 12 (12.9) | 27 (9.9) | |
| Grade IV | 5 (2.8) | 0 | 5 (1.8) | |
| Grade V | 1 (1) | 1 (1) | 2 (1) | |
| Immunotherapy discontinued due to toxicity, n (%) | 1 | |||
| Temporarily | 13 (7.2) | 10 (1) | 23 (8.4) | |
| Definitively | 27 (15) | 20 (21.5) | 47 (17.3) |